Bora Pharma Takes Over Emergent’s US Sterile Fill/Finish Plant

Bora Pharmaceuticals Co. Ltd., a leading pharmaceutical manufacturer, has finalized the acquisition of Emergent BioSolutions’ sterile production facility located in Baltimore-Camden, Maryland. This strategic move enhances Bora’s capabilities, adding drug product fill/finish services to its existing expertise in biologics drug substances.

The 87,000-square-foot facility now under Bora's ownership specializes in producing sterile injectables. It features four fill lines for both clinical and commercial aseptic fill/finish of vials and pre-filled syringes. The facility also offers lyophilization, formulation development, and various support services.

Earlier this year, Bora finalized the acquisition of Upsher-Smith Laboratories, a generics manufacturer and marketer based in Minnesota. This acquisition expands Bora’s production capacity, adding two oral dosage manufacturing sites in Plymouth and Maple Grove, Minnesota. With this addition, Bora's global CDMO network now comprises ten top-tier manufacturing facilities, providing customers with a wide range of dose forms and delivery technologies.

“Following on the heels of our recent acquisition of Upsher-Smith Laboratories, the Camden facility extends our presence in North America, expands our offering for our biologics customers, and advances us further in our goal to become a full service global CDMO. We look forward to further enhancing the capabilities at the site and welcoming the hugely talented team in Camden to our global family,” stated Bobby Sheng, Chairman and CEO of Bora Group.